Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings
Top Cited Papers
Open Access
- 18 February 2025
- journal article
- research article
- Published by Springer Nature in Nature Genetics
- Vol. 57 (3) , 563-571
Abstract
Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality, with pathogenic variants found in about a third of cases. Large-scale genome-wide association studies (GWAS) demonstrate that common genetic variation contributes to HCM risk. Here we derive polygenic scores (PGS) from HCM GWAS and genetically correlated traits and test their performance in the UK Biobank, 100,000 Genomes Project, and clinical cohorts. We show that higher PGS significantly increases the risk of HCM in the general population, particularly among pathogenic variant carriers, where HCM penetrance differs 10-fold between those in the highest and lowest PGS quintiles. Among relatives of HCM probands, PGS stratifies risks of developing HCM and adverse outcomes. Finally, among HCM cases, PGS strongly predicts the risk of adverse outcomes and death. These findings support the broad utility of PGS across clinical settings, enabling tailored screening and surveillance and stratification of risk of adverse outcomes.Keywords
All Related Versions
This publication has 60 references indexed in Scilit:
- Rare and Common Genetic Variation Underlying the Risk of Hypertrophic Cardiomyopathy in a National BiobankJAMA Cardiology, 2022
- Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic CardiomyopathyJACC, 2021
- Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy—Are there predictors of appropriate therapy?Heart Rhythm, 2021
- Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic CardiomyopathyJAMA Cardiology, 2020
- Effect of Gender and Genetic Mutations on Outcomes in Patients With Hypertrophic CardiomyopathyThe American Journal of Cardiology, 2018
- Polygenic EpidemiologyGenetic Epidemiology, 2016
- New Perspectives on the Prevalence of Hypertrophic CardiomyopathyJACC, 2015
- Long-Term Outcomes After Medical and Invasive Treatment in Patients With Hypertrophic CardiomyopathyJACC: Heart Failure, 2014
- GCTA: A Tool for Genome-wide Complex Trait AnalysisThe American Journal of Human Genetics, 2011
- Prevalence of hypertrophic cardiomyopathy in a Population-Based sample of American Indians aged 51 to 77 years (the Strong Heart Study)**The opinions expressed in this report are those of the authors and do not necessarily reflect the views of the Indian Health Service.The American Journal of Cardiology, 2004